Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
105.9 USD | -0.01% | -1.52% | -3.79% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.79% | 184B | |
-0.90% | 107B | |
-3.06% | 69.44B | |
+3.67% | 50.37B | |
+8.79% | 44.82B | |
+3.40% | 41.53B | |
+3.19% | 26.84B | |
+3.79% | 26.73B | |
+15.23% | 25.71B | |
-0.70% | 24.34B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Stifel Nicolaus Adjusts Abbott Laboratories Price Target to $115 From $125, Maintains Buy Rating